Dupilumab Found to Improve Clinical, Histologic Aspects of Eosinophilic Esophagitis
February 26, 2022

AAAAI 2022: New study found patients with eosinophilic esophagitis who received dupilumab experienced clinically meaningful improvements in symptoms.

Dupilumab Significantly Decreased Itch and Hives in Patients with Chronic Spontaneous Urticaria
February 26, 2022

Dupilumab significantly reduced itch and hives in patients with H1 antihistamine-resistant chronic spontaneous urticaria, according to new research.

Racial/Ethnic Bias Found in Asthma Clinical Trials Used to Update NHLBI Guideline
February 22, 2022

In the majority of studies that reported racial/ethnic data, White participants were highly overrepresented and Black/Hispanic/all Other underrepresented.

Tezepelumab Reduced Number of Symptomatic Days in Adults and Children with Severe, Uncontrolled Asthma
February 17, 2022

Patients with severe, uncontrolled asthma given tezepelumab experienced a reduction in asthma symptomatic days, found a new analysis of the NAVIGATOR trial.

Tezepelumab Found Effective in Reducing Exacerbations in Moderate-to-Severe, Uncontrolled Asthma
February 11, 2022

Tezepelumab significantly reduced exacerbations that required hospitalization or an emergency department visit in a new analysis of patients with moderate-to-severe, uncontrolled asthma.

New Study Identifies Key Risk Factors Likely to Accelerate a COPD Diagnosis in Patients with Asthma
February 08, 2022

New research highlights several key risk factors that are likely to accelerate the progression from asthma to COPD, including older age and prior tobacco use.

Severe Asthma Endotypes: A Test on Features, Assessment & Treatment
February 08, 2022

How familiar are you with mechanistic features of severe asthma, specific biomarker level cut offs, and impact of comorbid disease on choice of biologic treatment?

Severe Uncontrolled Asthma: 5 Questions on Key Characteristics
February 08, 2022

Optimal use of biologic therapy for severe uncontrolled asthma rests on understanding of the disease itself. Try this quick quiz to test your knowledge.

Tezepelumab Reduced Inflammatory Biomarkers of Severe Asthma in as Little as 2 Weeks
February 07, 2022

New data from the phase 3 NAVIGATOR trial found tezepelumab treatment reduced inflammatory biomarkers of severe, uncontrolled asthma in as little as 2 weeks.

Study: Prior Oral Corticosteroid Use, Hospitalization Raise Risk for Poor COVID-19 Outcomes in Adults with Asthma
February 03, 2022

Adults with asthma who had a prior hospitalization or required 2 or more courses of oral corticosteroids were at increased risk of poor COVID-19 outcomes, according to a new study.